Ironwood Pharmaceuticals Inc
IRWD
NASDAQ
Biotechnology
$4.31
USD
+0.23 (+5.64%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $686.57M
Volume 2.3M
Revenue
$389.32M
TTM
+26.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$129.87M
TTM
+1747.0%
YoY
Operating Cash Flow
$185.56M
TTM
+518.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 85.2 | 122.1 | 47.7 | 106.5 | 113.0 |
YoY Growth | -9.7% | +33.3% | -47.3% | +158.9% | +32.6% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 85.2 | 122.1 | 47.7 | 106.5 | 113.0 |
Selling, General & Administrative | 16.8 | 21.9 | 19.3 | 12.0 | 11.3 |
Other Operating Expenses | -0.3 | 2.2 | -0.3 | -0.0 | 0.0 |
Total Operating Expenses | 39.9 | 46.6 | 40.9 | 33.9 | 33.7 |
Operating Income | 45.3 | 75.5 | 6.8 | 72.6 | 79.3 |
EBITDA | 45.5 | 78.2 | 7.0 | 73.0 | 79.8 |
Other Income / Expense | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
Total Other Income / Expense | -7.5 | -7.5 | -6.4 | -7.4 | -5.6 |
Income Before Income Taxes | 37.8 | 68.0 | 0.5 | 65.2 | 73.7 |
Income Taxes | 14.2 | 27.9 | 2.7 | 24.4 | 22.4 |
Net Income | 23.6 | 40.1 | -2.3 | 40.8 | 51.3 |
Consolidated Net Income / Loss | 23.6 | 40.1 | -2.3 | 40.8 | 51.3 |
Net Income Attributable to Common Shareholders | 23.6 | 40.1 | -2.3 | 40.8 | 51.3 |
Basic EPS | $0.15 | $0.25 | -$0.01 | $0.25 | $0.31 |
Diluted EPS | $0.14 | $0.23 | -$0.02 | $0.24 | $0.31 |
Basic Shares Outstanding | 161.7M | 162.2M | 162.5M | 163.5M | 164.4M |
Diluted Shares Outstanding | 176.8M | 177.8M | 136.4M | 166.7M | 167.2M |